King's College London

Research portal

Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates

Research output: Contribution to journalReview articlepeer-review

Standard

Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates. / Hasan, Mahbub; Jin, Peiqin; Laws, Mark et al.

In: DRUG DISCOVERY TODAY, Vol. 27, No. 1, 01.2022, p. 354-361.

Research output: Contribution to journalReview articlepeer-review

Harvard

Hasan, M, Jin, P, Laws, M & Rahman, M 2022, 'Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates', DRUG DISCOVERY TODAY, vol. 27, no. 1, pp. 354-361. https://doi.org/10.1016/j.drudis.2021.09.015

APA

Hasan, M., Jin, P., Laws, M., & Rahman, M. (2022). Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates. DRUG DISCOVERY TODAY, 27(1), 354-361. https://doi.org/10.1016/j.drudis.2021.09.015

Vancouver

Hasan M, Jin P, Laws M, Rahman M. Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates. DRUG DISCOVERY TODAY. 2022 Jan;27(1):354-361. https://doi.org/10.1016/j.drudis.2021.09.015

Author

Hasan, Mahbub ; Jin, Peiqin ; Laws, Mark et al. / Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates. In: DRUG DISCOVERY TODAY. 2022 ; Vol. 27, No. 1. pp. 354-361.

Bibtex Download

@article{f348a9055f81496492e213374cc99f44,
title = "Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates",
abstract = "In antibody–drug conjugates (ADCs), monoclonal antibodies (mAbs) act as carriers for a cytotoxic payload providing the therapy with targeted action against cells expressing a target cell surface antigen. An appropriate choice of mAb is crucial to developing a successful ADC for clinical development. However, problems such as immunogenicity, poor pharmacokinetic (PK) and pharmacodynamic(PD) profiles and variable drug–antibody ratios (DARs) plague ADCs. In this review, we detail recent mAb-based innovations and factors that should be considered to overcome these problems to achieve a new generation of more effective ADC therapeutics.",
author = "Mahbub Hasan and Peiqin Jin and Mark Laws and Miraz Rahman",
note = "Funding Information: The authors would like to thank the Commonwealth Scholarship Commission in the UK for supporting M.M.H. during his PhD studies. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2022",
month = jan,
doi = "https://doi.org/10.1016/j.drudis.2021.09.015",
language = "English",
volume = "27",
pages = "354--361",
journal = "DRUG DISCOVERY TODAY",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "1",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates

AU - Hasan, Mahbub

AU - Jin, Peiqin

AU - Laws, Mark

AU - Rahman, Miraz

N1 - Funding Information: The authors would like to thank the Commonwealth Scholarship Commission in the UK for supporting M.M.H. during his PhD studies. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2022/1

Y1 - 2022/1

N2 - In antibody–drug conjugates (ADCs), monoclonal antibodies (mAbs) act as carriers for a cytotoxic payload providing the therapy with targeted action against cells expressing a target cell surface antigen. An appropriate choice of mAb is crucial to developing a successful ADC for clinical development. However, problems such as immunogenicity, poor pharmacokinetic (PK) and pharmacodynamic(PD) profiles and variable drug–antibody ratios (DARs) plague ADCs. In this review, we detail recent mAb-based innovations and factors that should be considered to overcome these problems to achieve a new generation of more effective ADC therapeutics.

AB - In antibody–drug conjugates (ADCs), monoclonal antibodies (mAbs) act as carriers for a cytotoxic payload providing the therapy with targeted action against cells expressing a target cell surface antigen. An appropriate choice of mAb is crucial to developing a successful ADC for clinical development. However, problems such as immunogenicity, poor pharmacokinetic (PK) and pharmacodynamic(PD) profiles and variable drug–antibody ratios (DARs) plague ADCs. In this review, we detail recent mAb-based innovations and factors that should be considered to overcome these problems to achieve a new generation of more effective ADC therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85116890308&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.drudis.2021.09.015

DO - https://doi.org/10.1016/j.drudis.2021.09.015

M3 - Review article

VL - 27

SP - 354

EP - 361

JO - DRUG DISCOVERY TODAY

JF - DRUG DISCOVERY TODAY

SN - 1359-6446

IS - 1

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454